Patent application number | Description | Published |
20090162890 | IDENTIFYING THERAPEUTIC COMPOUNDS BASED ON THEIR PHYSICAL-CHEMICAL PROPERTIES - The present invention is directed to rapid and efficient methods of identifying therapeutic compounds by allowing only the most favorable molecules initially selected based on their physical-chemical profile falling within a range predefined by the physical-chemical/biological relationship of a previously tested small subset of compounds of same core structure to be assayed; and to the therapeutic compositions identified by said methods. | 06-25-2009 |
20090163529 | IDENTIFYING THERAPEUTIC COMPOUNDS BASED ON THEIR PHYSICAL-CHEMICAL PROPERTIES - The present invention is directed to rapid and efficient methods of identifying therapeutic compounds by allowing only the most favorable molecules initially selected based on their physical-chemical profile falling within a range predefined by the physical-chemical/biological relationship of a previously tested small subset of compounds of same core structure to be assayed; and to the therapeutic compositions identified by said methods. | 06-25-2009 |
20090291092 | TREATMENT OF MITOCHONDRIAL DISEASES WITH AN ERYTHROPOIETIN MIMETIC - Methods of treating mitochondrial disorders that are not respiratory chain disorders using compositions comprising EPO mimetic compounds or compounds capable of increasing endogenous EPO levels or stimulating erythropoiesis are disclosed. Methods of treating Friedreich's ataxia, Leigh's syndrome, or other disorders by increasing the expression of frataxin with an EPO mimetic compound or a compound capable of increasing endogenous EPO levels or stimulating erythropoiesis are also disclosed. | 11-26-2009 |
20100010100 | DERMATOLOGICAL COMPOSITIONS WITH ANTI-AGING AND SKIN EVEN-TONING PROPERTIES - The present invention relates to methods and compositions comprising benzoquinones such as Duroquinone, for the use of treating, regulating or preventing a skin condition characterized by oxidative stress or a degenerative process. Methods of preventing, lightening or reducing the appearance of visible and/or tactile discontinuities of the skin resulting from skin pigmentation or skin aging are also disclosed. | 01-14-2010 |
20100029706 | HYDROGENATED PYRIDO[4,3-b]INDOLES FOR THE TREATMENT OF OXIDATIVE STRESS - Methods of treating or suppressing oxidative stress diseases including mitochondrial diseases, impaired energy processing disorders, and diseases of aging such as diabetes and cancer with hydrogenated pyrido[4,3-b]indoles such as dimebolin, are disclosed. | 02-04-2010 |
20100029784 | NAPHTHOQUINONE COMPOSITIONS WITH ANTI-AGING, ANTI-INFLAMMATORY AND SKIN EVEN-TONING PROPERTIES - The present invention relates to methods and compositions comprising naphthoquinones such as 2,3-dimethylnaphthalene-1,4-dione, for the use of treating, regulating or preventing a skin condition characterized by oxidative stress or a degenerative process. Methods of preventing, lightening or reducing the appearance of visible and/or tactile discontinuities of the skin resulting from skin pigmentation or skin aging are also disclosed. | 02-04-2010 |
20100056429 | TREATMENT OF RESPIRATORY CHAIN DISORDERS USING COMPOUNDS HAVING ERYTHROPOIETIN OR THROMBOPOIETIN ACTIVITY - Methods of treating mitochondrial respiratory chain disorders using compounds having erythropoietin activity or thrombopoietin activity are disclosed. Indicators for assessing the efficacy of treatment are discussed. | 03-04-2010 |
20100063161 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS - Methods of treating or suppressing pervasive developmental disorders (PDDs) including; autistic disorder, Asperger's syndrome, childhood disintegrative disorder (CDD), Rett's disorder, and PDD-not otherwise specified (PDD-NOS) or attention deficit/hyperactivity disorder (ADHD) comprising administering to a subject in need thereof a therapeutically effective amount of one or more compounds as disclosed herein. | 03-11-2010 |
20100222436 | REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS - Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention, such as alpha-tocopherol quinone. Methods and compounds useful in treating other disorders are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed. | 09-02-2010 |
20100273892 | FORMULATIONS OF TOCOTRIENOL QUINONES FOR THE TREATMENT OF OPHTHALMIC DISEASES - A formulation, comprising an ophthalmically effective amount of one or more tocotrienol quinones, particularly of alpha-tocotrienol quinone is disclosed. Use of a formulation comprising one or more tocotrienol quinones for the prevention, reduction, amelioration or treatment of ophthalmic disorders that are associated with a neurodegenerative or trauma disorder is also discussed. A method of treating or controlling the ocular symptoms associated with neurodegenerative diseases or trauma with a formulation comprising one or more tocotrienol quinones is also discussed. A method of treating or controlling the ocular symptoms associated with mitochondrial myopathies with a formulation comprising one or more tocotrienol quinones is also discussed. | 10-28-2010 |
20100273894 | TREATMENT OF LEBER'S HEREDITARY OPTIC NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH TOCOTRIENOL QUINONES - The present invention relates to methods of treating Leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones, including alpha-tocotrienol quinone, in order to alleviate symptoms of the disease. | 10-28-2010 |
20110046156 | TREATMENT OF HEARING AND BALANCE IMPAIRMENTS WITH REDOX-ACTIVE THERAPEUTICS - Compositions and methods are provided for prophylactic or therapeutic treatment of a mammal for hearing or balance impairments involving neuronal damage, loss, or degeneration, by administration of a therapeutically effective amount of a redox-active therapeutic. Also provided are improved compositions and methods for treatments requiring administration of a pharmaceutical having an ototoxic side-effect in combination with a therapeutically effective amount of a redox-active therapeutic to treat the ototoxicity. | 02-24-2011 |
20110142834 | TREATMENT OF HEARING AND BALANCE IMPAIRMENTS USING COMPOUNDS HAVING ERYTHROPOIETIN ACTIVITY - Compositions and methods are provided for prophylactic or therapeutic treatment of a mammal for hearing or balance impairments involving neuronal damage, loss, or degeneration, preferably of spiral ganglion neurons, by administration of a therapeutically effective amount of one or more molecules having erythropoietin activity selected from EPO, or a biosimilar, a variant, or a mutant thereof; a protein or peptide mimetic of EPO; a small molecule mimetic of EPO and an erythropoiesis stimulating agent. Also provided are improved compositions and methods for treatments of ototoxicity requiring administration of a pharmaceutical having an ototoxic side-effect in combination with a therapeutically effective amount of a molecule having erythropoietin activity. | 06-16-2011 |
20110172312 | TREATMENT OF LEIGH SYNDROME AND LEIGH-LIKE SYNDROME WITH TOCOTRIENOL QUINONES - The present invention relates to methods of treating Leigh Syndrome and Leigh-like Syndrome with tocotrienol quinones, including alpha-tocotrienol quinone, in order to alleviate symptoms of the disease. | 07-14-2011 |
20110207828 | METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA - The present invention provides methods for the treatment, amelioration, or prevention of a symptom of neuronal damage associated with cerebral ischemia comprising administering compositions comprising a compound of Formula I. | 08-25-2011 |
20110269776 | TREATMENT OF OXIDATIVE STRESS DISORDERS INCLUDING CONTRAST NEPHROPATHY, RADIATION DAMAGE AND DISRUPTIONS IN THE FUNCTION OF RED CELLS - Methods of treating or suppressing oxidative stress diseases and symptoms related to oxidative stress affecting normal electron flow in the cells or caused by reactive oxygen species with redox-active therapeutics. Use of redox-active therapeutics for the reduction, suppression or treatment of oxidative stress induced by chemical agents such as contrast agents and other nephrotoxic agents, by radiation exposure, and by disruptions in the transport of oxygen to tissues, is disclosed. | 11-03-2011 |
20120122969 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH TOCOTRIENOLS OR TOCOTRIENOL ENRICHED EXTRACTS - Methods of treating or suppressing Pervasive Developmental Disorders (PDDs) including; Autistic Disorder, Asperger's Disorder, Childhood Disintegrative Disorder (CDD), Rett's Disorder, and PDD-Not Otherwise Specified (PDD-NOS) comprising administering to a subject in need thereof a therapeutically effective amount of a tocotrienol, a tocotrienol ester, a tocotrienol ether, a tocotrienol enriched extract or mixtures thereof. | 05-17-2012 |
20120136048 | TOPICAL, PERIOCULAR, OR INTRAOCULAR USE OF TOCOTRIENOLS FOR THE TREATMENT OF OPHTHALMIC DISEASES - A method for preventing, reducing, ameliorating or treating ophthalmic disorders associated with neurodegenerative diseases or trauma, comprising the topical, periocular, or intraocular application of an ophthalmic formulation comprising a therapeutically effective amount of one or more ophthalmic agents selected from the group consisting of alpha-tocotrienol, beta-tocotrienol, gamma-tocotrienol, delta-tocotrienol, or esters or mixtures thereof is disclosed. Use of tocotrienols for the prevention, reduction, amelioration or treatment of ophthalmic disorders that are, or that are associated with, mitochondrial diseases is also discussed. Topical ophthalmic formulations comprising tocotrienols are also discussed. | 05-31-2012 |
20120295985 | METHODS FOR IMPROVING BLOOD GLUCOSE CONTROL - The present invention is concerned with a method for improving blood glucose control or for preventing or treating a condition requiring increasing insulin sensitivity or reducing insulin resistance in a subject in need of such control which comprises administering to the subject a composition comprising a therapeutically effective amount of one or more quinones of Formula I. | 11-22-2012 |
20130053450 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS - Methods of treating or suppressing pervasive developmental disorders (PDDs) including; autistic disorder, Asperger's syndrome, childhood disintegrative disorder (CDD), Rett's disorder, and PDD-not otherwise specified (PDD-NOS) or attention deficit/hyperactivity disorder (ADHD) comprising administering to a subject in need thereof a therapeutically effective amount of one or more compounds as disclosed herein. | 02-28-2013 |
20130109759 | FORMULATIONS OF QUINONES FOR THE TREATMENT OF OPHTHALMIC DISEASES | 05-02-2013 |
20130267538 | TREATMENT OF MITOCHONDRIAL DISEASES - The invention relates the method of treatment or amelioration of mitochondrial disorders such as Alzheimer's disease, Parkinson's disease, Friedreich's ataxia (FRDA), cerebellar ataxias, Leber's hereditary optic neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), Myoclonic Epilepsy with Ragged Red Fibers (MERFF), amyotrophic lateral sclerosis (ALS), motor neuron diseases, Huntington's disease, macular degeneration, and epilepsy, with chroman derivatives of Formula I or Formula II as described herein. | 10-10-2013 |
20130345312 | TREATMENT OF MITOCHONDRIAL DISEASES WITH NAPHTHOQUINONES - Methods of treating, preventing or suppressing symptoms associated with mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), dominant optic atrophy (DOA); mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), Leigh syndrome or Kearns-Sayre Syndrome (KSS) with compounds of Formula (I) are disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods are also disclosed. | 12-26-2013 |
20140031432 | TREATMENT OF MITOCHONDRIAL DISEASES WITH VITAMIN K - Methods of treating, preventing or suppressing symptoms associated with mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), dominant optic atrophy (DOA); mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), Leigh syndrome or Kearns-Sayre Syndrome (KSS) with vitamin K are disclosed. | 01-30-2014 |
20140031433 | FORMULATIONS OF TOCOTRIENOL QUINONES FOR THE TREATMENT OF OPHTHALMIC DISEASES - A formulation, comprising an ophthalmically effective amount of one or more tocotrienol quinones, particularly of alpha-tocotrienol quinone is disclosed. Use of a formulation comprising one or more tocotrienol quinones for the prevention, reduction, amelioration or treatment of ophthalmic disorders that are associated with a neurodegenerative or trauma disorder is also discussed. A method of treating or controlling the ocular symptoms associated with neurodegenerative diseases or trauma with a formulation comprising one or more tocotrienol quinones is also discussed. A method of treating or controlling the ocular symptoms associated with mitochondrial myopathies with a formulation comprising one or more tocotrienol quinones is also discussed. | 01-30-2014 |
20140039065 | TREATMENT OF LEBER'S HEREDITARY OPTIC NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH TOCOTRIENOL QUINONES - The present invention relates to methods of treating Leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones, including alpha-tocotrienol quinone, in order to alleviate symptoms of the disease. | 02-06-2014 |
20140206772 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS - Methods of treating or suppressing pervasive developmental disorders (PDDs) including; autistic disorder, Asperger's syndrome, childhood disintegrative disorder (CDD), Rett's disorder, and PDD—not otherwise specified (PDD-NOS) or attention deficit/hyperactivity disorder (ADHD) comprising administering to a subject in need thereof a therapeutically effective amount of one or more compounds as disclosed herein. | 07-24-2014 |
20140249160 | TREATMENT OF HEARING AND BALANCE IMPAIRMENTS WITH REDOX-ACTIVE THERAPEUTICS - Compositions and methods are provided for prophylactic or therapeutic treatment of a mammal for hearing or balance impairments involving neuronal damage, loss, or degeneration, by administration of a therapeutically effective amount of a redox-active therapeutic. Also provided are improved compositions and methods for treatments requiring administration of a pharmaceutical having an ototoxic side-effect in combination with a therapeutically effective amount of a redox-active therapeutic to treat the ototoxicity. | 09-04-2014 |
20140343166 | TREATMENT OF LEIGH SYNDROME AND LEIGH-LIKE SYNDROME WITH TOCOTRIENOL QUINONES - The present invention relates to methods of treating Leigh Syndrome and Leigh-like Syndrome with tocotrienol quinones, including alpha-tocotrienol quinone, in order to alleviate symptoms of the disease. | 11-20-2014 |
20150057363 | TREATMENT OF METHYLMALONIC ACIDURIA, ISOVALERIC ACIDURIA, AND OTHER ORGANIC ACIDURIAS WITH TOCOTRIENOL QUINONES - The present invention relates to methods of treating methylmalonic aciduria and other organic acidurias with tocotrienol quinones, including alpha-tocotrienol quinone, in order to alleviate symptoms of the disease. | 02-26-2015 |